Efficacy and Safety HCP

ASPIRIN IS PROVEN TO REDUCE THE RISK OF RECURRENT MI AND ISCHEMIC STROKE1,*

    Bayer® Aspirin can help save lives.

    STUDIES SHOW THAT

    Aspirin can help reduce the risk of recurrent:

    31% decline icon

    Myocardial Infarction by

    22% decline icon

    Ischemic Stroke by

    STUDIES ALSO SHOW THAT

    Discontinuing an aspirin regimen can increase the risk of recurrent:

    63% growth icon

    Myocardial Infarction by

    40% growth icon

    Ischemic Stroke by

    Aspirin plays a critical role in dual antiplatelet therapy.4-6

    For maximum efficacy, remind patients to continue taking Bayer® Aspirin with their prescription antiplatelet therapy.

    Your Bayer® Aspirin Recommendation Matters

    Icon_Stop watch

    Every 40 seconds

    an American has a heart attack or stroke. And after a primary CV event, the risk for recurrent events increases.7,8

    Icon_Heart

    ~130,000 deaths annually

    could be avoided, if patients followed their doctors’ recommendations for post-MI preventive measures like a low-dose aspirin regimen.9

    Icon_Calendar

    91% of patients

    with CV disease adhered to the aspirin regimen recommended by their doctors for secondary prevention.10,†

    A well-established safety profile when used as directed

    bleed

    <1% of patients taking aspirin for secondary prevention experienced a serious, nonfatal GI bleed11,‡

    prevent death

    1.5 deaths can be prevented for every nonfatal GI bleed caused by aspirin use11,‡

    Bayer_LD_Bottle2

    Bayer® Aspirin 81 mg is recommended as part of a secondary prevention regimen—with an enteric coating to help with GI tolerability.

    icon

    Aspirin remains the cornerstone of cardiovascular health in secondary prevention, backed by rigorous scientific support1,12

    Image

    It's the #1 doctor-recommended aspirin brand

    *Nonfatal myocardial infarction or ischemic stroke.
    †A cross-sectional analysis of a representative sample, 3599 US adults aged ≥40 years from the National Health and Nutrition Examination Survey.10
    ‡In a meta-analysis of 6300 patients.11


    References: 1. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-1860. 2. García Rodríguez LA, Cea-Soriano L, Martín-Merino E, Johansson S. Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. BMJ. 2011;343:d4094. doi:10.1136/bmj.d4094 3. García Rodríguez LA, Cea Soriano L, Hill C, Johansson S. Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology. 2011;76(8):740-746. doi:10.1212/WNL.0b013e31820d62b5 4. Plavix® (clopidogrel bisulfate). Prescribing information. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; 2021. 5. Brilinta® (ticagrelor). Prescribing information. AstraZeneca Pharmaceuticals LP; 2021. 6. Effient® (prasugrel). Prescribing information. Eli Lilly and Company; 2019. 7. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics—2019 update. A report from the American Heart Association. Circulation. 2019;139(10): e56-e528. doi:10.1161/CIR.0000000000000659 8. American Stroke Association website. https//www.stroke.org/en/life-after-stroke/preventing-another-stroke. Accessed June 3, 2021. 9. Packard KA, Hilleman DE. Adherence to therapies for secondary prevention of cardiovascular disease: a focus on aspirin. Cardiovasc Ther. 2016;34(6):415-422. doi:10.1111/1755-5922.12211 10. Gu Q, Dillon CF, Eberhardt MS, Wright JD, Burt VL. Preventive aspirin and other antiplatelet medication use among U.S. adults aged ≥40 years: data from the national health and nutrition examination survey, 2011-2012. Public Health Rep. 2015;130(6):643-654. 11. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002;162(19):2197-2202. 12. Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036–1046. doi:10.1016/S0140-6736(18)31924-X